UBS Lowers PT on Danaher Corporation (DHR) to $225 From $240, Keeps a Buy Rating

Danaher Corporation (NYSE:DHR) is one of the best strong buy healthcare stocks to buy now. On July 23, UBS lowered the firm’s price target on Danaher Corporation (NYSE:DHR) to $225 from $240, while maintaining a Buy rating on the shares.

The firm told investors in a research note that while Danaher Corporation (NYSE:DHR) reported Q2 2025 results in line with expectations, its Q3 2025 guidance was slightly below estimates, resulting in a price target downgrade.

Danaher Corporation (NYSE:DHR) reported Q2 2025 earnings on July 22, with revenues rising 3.5% year-over-year to $5.9 billion and non-GAAP core revenue increasing 1.5% year-over-year. Net earnings for the quarter reached $555 million, or $0.77 per diluted common share.

For Q3 2025, Danaher Corporation (NYSE:DHR) expects non-GAAP core revenue to grow in the low single digits year-over-year.

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.

Its Biotechnology segment offers a range of equipment and consumables for biological medicines. In contrast, the Life Diagnostics segment offers clinical instruments, devices, consumables, and other services for diagnosing and treating diseases.

While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.